| P/E (FY) | — | Sales (TTM) | $74.1M |
| Earnings (TTM) | -$114.7M | ROE | −20.18% |
| Net Margin | −282.83% | ROIC | −23.47% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 20.07% |
Protagonist Therapeutics is a discovery and development company in the United States. It is developing icotyde, an investigational oral peptide for moderate-to-severe plaque psoriasis, and rusfertide, an injectable hepcidin mimetic in Phase 3 for polycythemia vera. Its pipeline also includes PN-881, an oral peptide IL-17 antagonist in Phase 1, PN-477 and PN-458 for obesity, PN-8047, and an IL-4R alpha antagonist for atopic dermatitis.
| Market Cap | $8.80B | Trading Days | 2498 |
| 52W High | 143.29 |
| 52W Low | 50.48 |
| % Off High | −4.50% |
| YTD | 56.68% | 1Y | 143.23% |
| 3Y | 616.82% | 5Y | 191.21% |
| Since incept. (ann.) | 28.01% |
| Ann. Volatility (1Y) | 51.98% | Ann. Volatility (3Y) | 55.11% |
| Sharpe (1Y) | 2.00 | Sharpe (3Y) | 1.47 |
| Max Drawdown (1Y) | −16.38% | Max Drawdown (3Y) | −31.58% |
| Beta (3Y, vs SPY) | 0.66 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.84B | — |
| SYRE | Spyre Therapeutics, Inc. | $8.68B | — |
| NUVL | Nuvalent, Inc. | $9.01B | — |
| IONS | IONIS PHARMACEUTICALS INC | $9.14B | — |
| ALKS | Alkermes plc. | $8.47B | 35.3 |
| TGTX | TG THERAPEUTICS, INC. | $8.40B | 19.8 |
| PRAX | Praxis Precision Medicines, Inc. | $8.25B | — |
| CYTK | CYTOKINETICS INC | $9.89B | — |
| SMMT | Summit Therapeutics Inc. | $10.01B | — |
| LQDA | Liquidia Corp | $7.72B | — |
| CORT | CORCEPT THERAPEUTICS INC | $10.11B | 114.9 |
| GPCR | Structure Therapeutics Inc. | $10.21B | — |
